Christine Murray

Christine Murray was appointed as a member of the Board in January 2019. Ms. Murray serves as Senior Vice President of Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Prior to joining Ultragenyx Pharmaceutical, Inc, Ms. Murray was Vice President of Regulatory Affairs at Raptor Pharmaceuticals, a company that developed products for serious, ultra-rare diseases, from 2015 to 2017.

Raptor Pharmaceuticals was acquired by Horizon Pharma plc. in 2017. Ms. Murray also held positions of increasing responsibility at a number of biopharma companies, including Achaogen, Inc. from 2011-2015, Alexza Pharmaceuticals, Inc. from 2008–2011, and Gilead Sciences, Inc. from 2004-2008, in Regulatory Affairs and Quality Assurance.

Ms. Murray holds a BS in Biochemistry from Liverpool University, UK, an MS in Clinical Biochemistry from the University of Newcastle-upon-Tyne, UK, and a Regulatory Affairs Certification from the University of California Santa Cruz Extension.